Oxidative status and the response to pegylated-interferon alpha2A plus ribavirin in chronic genotype 4 HCV hepatitis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Oxidative status and the response to pegylated-interferon alpha2A plus ribavirin in chronic genotype 4 HCV hepatitis ; Vol. 12, 2013
EXCLI journal ; Vol. 12, 2013
- Classification
-
Medizin, Gesundheit
- Creator
-
Ahmed, Mohammed Mahmound
Abdel-Salam, Omar M. E.
Mohammed, Nadia A.
Habib, Dawoud Fakhry
Gomaa, Hewida Ez-eldin
- Handle
-
2003/32944
- URN
-
urn:nbn:de:101:1-201605259983
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ahmed, Mohammed Mahmound
- Abdel-Salam, Omar M. E.
- Mohammed, Nadia A.
- Habib, Dawoud Fakhry
- Gomaa, Hewida Ez-eldin
Other Objects (12)
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
Heterogeneity of hepatitis C virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6
Heterogeneity of hepatitis C-virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients
Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis
Severe psoriasis emerged after treatment of chronic HCV co-infection with pegylated-interferon and ribavirin, supported by neutropenia rescue with repeated filgrastim administration
Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
Heterogeneity of hepatitis C virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6
Heterogeneity of hepatitis C-virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients
Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis
Severe psoriasis emerged after treatment of chronic HCV co-infection with pegylated-interferon and ribavirin, supported by neutropenia rescue with repeated filgrastim administration
Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
Heterogeneity of hepatitis C virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6
Heterogeneity of hepatitis C-virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients
Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis
Severe psoriasis emerged after treatment of chronic HCV co-infection with pegylated-interferon and ribavirin, supported by neutropenia rescue with repeated filgrastim administration
Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy